top of page

FemTech Investment Overview
Lack of investment remains the key barrier for FemTech development, along with insufficient R&D funding and lack of public support. Despite growing interest in FemTech companies, only 4% of tech investment in life science targets FemTech.
In 2021, the global VC investment in FemTech crossed $1 billion for the first time. One of the reasons the industry is not getting significant VC funding is the poor track record of sizable exits.

Source: Pitchbook Data
As of December 2021, the total funding in the FemTech sector was about $14 billion.
The General Health Care subsector leads the market by total funding of approximately $3.4 billion at the end of 2021.
The two other largest subsectors by funding are Reproductive Health and Contraception ($2.7 billion) and Longevity ($2.6 billion).

Source: FemTech Analytics, Crunchbase
Many companies have gone through significant improvements and changes during the last few years. The more companies become FemTech-focused, the more investment appears in the industry, and therefore, new players and decision-makers emerge on the global FemTech market. Accounting for nearly 65%, the US has a leading number of FemTech investors (in FemTech-focused companies). More than $10 billion was invested in US-based companies, as of December 2021.

